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The CD20-directed monoclonal antibody rituximab established a new era in lymphoma therapy. Since then
other epitopes on the lymphoma surface have been identified as potential targets for monoclonal antibodies
(mAb). While most mAbs eliminate lymphoma cells mainly by antibody-dependent cellular cytotoxicity,
complement-dependent cytotoxicity or direct cell death, others counter mechanisms utilized by malignant cells
to evade immune surveillance. Expression of PD-L1 on malignant or stromal cells in the tumor environment for
example leads to T-cell anergy. Targeting either PD-1 or PD-L1 via mAbs can indirectly eliminate cancer cells by
unblocking the host intrinsic immune response. Yet another mechanism of targeted therapy with mAbs are
bi-specific T-cell engagers (BiTE) such as blinatumomab, which directly engages the host immune cells. These
examples highlight the broad spectrum of available therapies targeting the lymphoma surface with mAbs utilizing
both passive and active immune pathways. Many of these agents have already demonstrated significant activity in
clinical trials. In this review we will focus on novel CD20-directed antibodies as well as mAbs directed against newer
targets like CD19, CD22, CD40, CD52 and CCR4. In addition we will review mAbs unblocking immune checkpoints and
the BiTE blinatumomab. Given the success of mAbs and the expansion in active and passive immunotherapies, these
agents will play an increasing role in the treatment of lymphomas.
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In 1997 the CD20-directed monoclonal antibody (mAb)
rituximab became the first mAb approved for the treat-
ment of lymphoma after it demonstrated significant
single agent activity in indolent B-cell lymphomas [1].
Since then rituximab has become an indispensable
component in the treatment of all types of B-cell Non-
Hodgkin lymphomas (NHL), both alone and in combin-
ation with chemotherapeutic agents [2].
While rituximab can lead to direct cytotoxicity by in-
duction of apoptosis, it also eliminates lymphoma cells
by antibody-dependent cellular cytotoxicity (ADCC) and
complement-dependent cytotoxicity [3]. Its success has
spawned an immense interest in using the hosts’ immune
system in selectively targeting tumor cells by attacking
tumor-specific surface antigens. These surface epitopes
represent ideal targets as they allow effective anticancer
therapy while relatively sparing normal tissues.
mAbs represent the cornerstone of passive immuno-
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unless otherwise stated.targeting a desired antigen and infusion into patients with
disease. Methods to potentially increase their efficacy
include conjugation of mAbs with potent cell toxin or
radioisotopes, exemplified by antibody-drug conjugates
(ADC) and radioimmunotherapy (RIT) respectively. An-
other more recent mode of passive immunotherapy is
termed adoptive T-cell transfer: autologous T-cells with
genetically modified T-cell receptors (chimeric antigen re-
ceptors; CARs) that specifically recognize a tumor epitope
are reinfused and exert their newly acquired antilym-
phoma potency in the host [4]. BiTEs or bispecific T cell
engagers are also examples for newer passive therapy that
activates T cell destruction of lymphoma cells.
Active immunotherapy on the other hand enables the
patient’s own immune system to re-engage into recog-
nizing malignant cells which originally escaped immune
surveillance. The classical example for active immuno-
therapy is tumor vaccines. More recently antibodies di-
rected against CTLA4 or the PD-1/PD-L1 pathway, which
unblock immune checkpoints, have demonstrated signifi-
cant antitumor activity [3].
This review focuses on recent advances in targeting
the lymphoma surface directly or indirectly with mAbsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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(Figure 1), and agents that have either just reached the
clinical practice or hold promise to change standard of
care. Lymphoma therapy with ADCs, RIT, vaccines or
adoptive T-cell transfer is reviewed elsewhere [3,5-7].
Monoclonal antibodies against B-cell antigens
Targeting CD20
CD20 is a surface antigen found on all mature B-cells.
Its main function is to activate B-cells, allowing prolifer-
ation and differentiation. As it is also present on most
mature B-cell NHL cells, it represents an ideal thera-
peutic target. While mAbs against CD20 target mature
B-cells, they spare B cell progenitors, allowing normal
B-cell regeneration [2].
Rituximab was the first mAb to target CD20 and rep-
resents a type I mAbs that cause cell death through: [8]
a direct apoptotic effect; complement-dependent cyto-
toxicity (CDC), in which binding of the mAb activates
the complement cascade; and ADCC, in which immune
cells expressing Fcy receptors attack antibody-coated
cells. Certain polymorphisms in the FcyRIIIa protein
alter activation of effector cells causing less ADCC and
result in significantly lower response rates (RR) following
rituximab monotherapy [9-11]. Newer mAbs are being
designed to better target carriers of these polymorphisms
(Table 1).
Obinutuzumab (GA101; Gazyva™) represents a type II
mAb; while type I mAbs work primarily through CDC
by stabilizing CD20 on lipid rafts, type II mAbs work
mainly by direct cell death and ADCC [12-15]. Obinutu-
zumab is a glycoengineered CD20 mAb derived from
the murine Bly-1 antibody [16]. Afucosylation (which
increases affinity to Fc gamma receptor IIIa) of the FcFigure 1 Lymphoma cell surface targets for immunotherapy.
Abbreviations: BiTE, Bispecific T-cell Engager; CCR4, C-C Chemokine
Receptor Type 4.region leads to improved activation of effector cells [17].
leading to BCL-2 and caspase independent apoptosis, and
hypothetically circumvents resistance [12]. As compared to
rituximab, it results in increased ADCC and direct apop-
tosis both in vitro and in vivo [9,17]. Type II mAbs are
thought to have an advantage because type I mAbs are
faced with complement-resistance factors, depletion of
complement proteins [18], and bind C1q, which interferes
with FcyR binding and decreases ADCC [19]. Furthermore,
type II mAbs result in longer persisting anti-CD20 mAb
complexes [20] and higher binding affinity thereby increas-
ing ADCC.
In November 2013, obinutuzumab was FDA approved
for the treatment of previously untreated CLL in com-
bination with chlorambucil (Cb). In a phase 3 study in
treatment naïve elderly patients, Cb with obinutuzumab
showed superior RR and progression free survival [PFS]
compared to Cb alone and Cb with rituximab (complete
response [CR] rate 21%; overall response rate [ORR]
78%) [21]. In addition, obinutuzumab has been tested in
combination with other chemotherapeutic agents in CLL
[22] and more aggressive B-cell NHL, such as diffuse
large B-cell lymphoma (DLBCL) and mantle cell lymph-
oma (MCL) [23], demonstrating promising results. The
main non-hematologic side effects (SE) were grade 1 or 2
infusion-related reactions (IRRs) and the most common
hematologic SE was neutropenia.
Ofatumumab
Ofatumumab (HuMax-CD20; Arzerra®) is another hu-
manized CD20-directed mAb. It binds to both loop do-
mains of CD20 at a different epitope than rituximab and
induces CDC [24]. As compared with rituximab and obi-
nutuzumab, ofatumumab results in the greatest comple-
ment activation and antibody-dependent phagocytosis
(ADP) [25].
Ofatumumab is FDA-approved in combination with
chlorambucil for the treatment of CLL patients for
whom fludarabine-based therapy is considered inappro-
priate [26] and those who are refractory to fludarabine
and alemtuzumab [27]. The most common SE were IRRs
and infections that were grade I/II events. Additionally,
in combination with pentostatin and cyclophosphamide
it compared favorably to historical controls treated with
fludarabine, cyclophosphamide and rituximab (FCR)
[28-30]. When combined with fludarabine and cyclophos-
phamide (O-FC) the results were comparable to what has
been reported with other similar chemoimmunotherapy
(CIT) regimens [31]. Trials directly comparing rituximab-
based CIT to ofatumumab-based CIT in CLL are currently
ongoing.
Ofatumumab has also been tested in indolent and ag-
gressive NHL either as single agent or in combination
with chemotherapy [32-35]. It appears that while the
Table 1 Anti-CD20 monoclonal antibodies currently approved or being investigated in clinical trials for B-cell lymphomas
mAb Type of CD20antibody* Generation** Structure
Mechanism of action
(ADCC/CDC/PCD) Comparison to rituximab
Indications













++++/-/++++ Superior PCD/ADCC; no CDC CLL/NHL
Phase 2/3 Approved in 2013





I 1 Fully human IgG1 +++/++++/++ Superior CDC, decreased PCD CLL/NHL
Phase 2/3 Approved for
untreated CLL in
combination with CIb &
refractory CLL
[21-35]
Veltuzumab I 2 Humanized IgG1 ++/++/+
Longer “off-rate”, more avid
CD20 binding. can be given
subcutaneously
R/R NHL/CLL Phase 1/2 [36-38]









BM-ca I/II*** 3 Humanized IgG ++++/+++/++++
Different epitope, superior
ACDD, CDC and PCD
NHL
Phase 1 [42-44]
ADCC: Antibody dependent cellular cytotoxicity; CDC: Complement dependent cytotoxicity; CIb: chlorambucil; CLL: Chronic lymphocytic leukemia; DLBCL: Diffuse large B cell lymphoma; PCD: programmed cell death;
mAb: Monoclonal antibody; Moa: Mechanism of action; NHL: Non-Hodgkin lymphoma.
*Type of mAb: compared to a type I mAb, a type 2 mAb does not evoke a complement response, however, may have increased PCD/ADCC.
**Generations of mAB.
1st generation: originally approved mAB against a clinically validated target 2nd generation: follow-up antibodies with improved variable domains that target the same epitopes with higher or lower affinity, or have
different antibody formats, e.g. Pegylation and Fc-fusion proteins. 3rd generation: target different epitopes or trigger other mechanisms of action; often engineered for improved Fc-associated immune functions
or half-life.
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cacy compares favorably.
Veltuzumab
Veltuzumab is a humanized anti-CD20 mAb that was
constructed on the framework regions of the anti-CD22
mAb epratuzumab (see below). Structurally it differs
from rituximab by only one amino acid. It has a signifi-
cantly higher potency than rituximab in preclinical
models, exhibiting a greater CDC and possessing a slower
off-rate resulting in longer cell surface retention [36].
In a phase 1/2 study of 82 patients with refractory
NHL, the drug was well tolerated, with no serious side
effects. In patients with follicular lymphoma (FL) who
had prior exposure to rituximab, veltuzumab was associ-
ated with an ORR of 44% and a CR rate of 27% [37]. RR
were higher in rituximab-naïve patients (ORR 57%; CR/
CRu (unconfirmed CR) rate 43%). Among non-follicular
histologies, the ORR was 35%, with 27% achieving a CR.
Although developed for IV use, veltuzumab has been
shown to have similar efficacy as a SQ injection [38].
Ocrelizumab
Ocrelizumab is another humanized IgG1 anti-CD20
mAb. It differs from rituximab at the complementarity-
determining regions, and is derived from a different allo-
type of human Fc. Like rituximab, ocrelizumab works
through ADCC, CDC and apoptosis, although it has
been shown to have better ADCC and lower CDC. Im-
portantly, ocrelizumab has better binding to the low-
affinity variants of the Fcy receptor IIIa. Patients with
the high affinity variant of FcyRIIIa have shown superior
outcomes following rituximab compared with patients
with the low affinity variant; thus it is hypothesized that
ocrelizumab may have better clinical efficacy [9,11]. In a
phase 1/2 trial, ocrelizumab was tested as single agent in
patients with relapsed/refractory (R/R) FL [39]. Overall,
the drug was well tolerated, (a similar safety profile as
rituximab monotherapy) with an ORR of 38%, which is
comparable to rituximab re-treatment.
LY2469298
LY2469298 (AME-133v) is a humanized IgG1 anti-CD20
mAb with a 13–20 fold higher affinity to CD20 than
rituximab. A limited number of amino acid substitu-
tions in the Fc region of the mAb result in enhanced
ADCC (6-fold more potent in vitro) but with 50% less
CDC compared with rituximab [40]. and potentially
more efficacy than rituximab in those patients who
were carriers of the low affinity FcyRIIIa allele. In a
phase 1 trial of patients with previously treated FL who
were FCyRIIIa carriers, the drug was well tolerated; re-
sponses (PR or CR) were observed in 22% of patients
[41]. In a Japanese phase 1 study the ORR was 50% inpreviously rituximab-treated FL patients carrying the
FCyRIIIa variant [40].
BM-ca
BM-ca is a novel mAb targeting CD20 that recognizes a
unique epitope as compared to rituximab, and was stronger
than rituximab in ADCC and direct anti-cell proliferation
assays [42,43]. In phase I studies, it was shown to be well
tolerated with promising preliminary anti-lymphoma activ-
ity in B cell NHL (2 CR and 2 PR out of 12 patients) [44].
Targeting CD22
CD22 is a sialic acid-binding immunoglobulin (Ig)-like lec-
tin involved in cellular adhesion, regulation of B-cell hom-
ing and modulation of B-cell activation [45]. It is expressed
by pre-B, mature, and normal B-cells as well as in many
malignant B-lymphocytes [46]. During early B-cell develop-
ment it is found in the cytoplasm, then on the cell surface
of mature B-cells [47]. Quickly internalized when bound
by mAbs, it is then re-expressed on the cell membrane
after modulation, a property not found in CD20 [48,49].
This, and the role CD22 plays in B-cell signaling, makes it
an ideal target in lymphoid B-cell malignancies (Table 2).
Epratuzumab
The mAb targeting CD22 furthest along in development
is the IgG1 humanized mAb, epratuzumab. The actual
mechanism of epratuzumab has not been formally ex-
plored, but it is reasonable to assume that it includes
ADCC, CDC and direct cytotoxicity [50]. Single agent
epratuzumab has been studied in indolent as well as ag-
gressive NHL. In an early phase 1/2 trial, epratuzumab
was well tolerated and showed the best response in FL
(ORR 24%) [51], while 15% of patients with DLBCL
showed a response [52]. The drug was very well tolerated,
with no dose-limiting toxicity.
Epratuzumab plus rituximab has been tested in R/R
NHL and compared to single agent use, resulted in a
higher ORR of 47% with the highest RR again in FL
(64%) [53]. Another multicenter trial showed an ORR of
54% for patients with FL and 57% for small lymphocytic
lymphoma (SLL) [54]. The combination of epratuzumab
with rituximab was also studied in patients with newly
diagnosed FL, and the RR of was 88.2% [55].
In aggressive lymphomas, when combined with R-
CHOP for patients with DLBCL, the ORR was 96% [50],
which compares favorably with studies using R-CHOP
for upfront treatment. Of note, approximately 15% of
patients with DLBCL do not express CD22; in this trial
CD22-negative patients were ineligible [56].
Targeting CD19
CD 19 is a transmembrane glycoprotein that is ex-
pressed by normal and malignant B-cells from early
Table 2 Monoclonal antibodies directed against non-CD20 surface epitopes
mAB Target Structure Unique properties Indication tested Phase ofdevelopment References





Enhanced ADCC, no CDC NHL/DLBCL/ALL Phase 1/2 [60,61]
Lucatumumab
CD4O Humanized IgG1









DLBCL Phase 1 [71-76]
Alemtuzumab



















variable regions of two
antibodies.
Bispecific T-cell Engager DLBCL/ALL Phase 2/3 [118-120]
ADCC: Antibody dependent cellular cytotoxicity; ALL: Acute lymphoblastic leukemia; BiTE: Bispecific T-cell Engager; CDC: Complement dependent cytotoxicity; CLL:
Chronic lymphocytic leukemia; CTCL: Cutaneous T Cell Lymphoma; DLBCL: Diffuse large B cell lymphoma; HL: Hodgkin lymphoma; mAB: Monoclonal antibody;
MALT: Mucosa associated Lymphoid tissue lymphoma; Moa: Mechanism of action; MZL: Marginal zone lymphoma; NHL: Non Hodgkin lymphoma; PCD: programmed
cell death; PTCL: Peripheral T Cell Lymphoma.
*PD1 is mainly expressed on regulatory T cell surface, while its ligand PDL-1 is often expressed on malignant cells. Stimulation of this pathway results in immune
anergy towards malignant cells.
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[57,58]. It is found on a wide range of B-cell malignan-
cies, including those arising from early B-cell precursors,
which cannot be effectively targeted with CD20 Abs [57].
Like CD22, but unlike CD20, it is also efficiently internal-
ized. Its function encompasses regulating cell signaling
thresholds and serving as a co-stimulatory molecule for
B-cell receptor (BCR) signaling [59].
MEDI-551
MEDI-551 is an afucosylated anti-human CD19 mAb
with in vitro and in vivo activity against lymphoma [60].
Results from a phase 1 trial of single agent MEDI-551 in
R/R B-cell malignancies show an acceptable safety profile
and ORR of 24%, 24%, and 31% in heavily pre-treated
CLL, DLBCL and FL patients respectively [61]. Phase 2
trials in DLBCL patients are currently recruiting.
Targeting CD40
CD40 is a type-1 transmembrane protein and expressed
in more than 90% of B-cell malignancies [62-65]. It is
thought to have a greater range of expression than CD20
and is present in the pro-B to the plasma cell phase of
B-cell development. Studies have showed that activation
of CD40 results in enhanced survival of neoplastic B-cells,
thus targeting CD40 with mAbs could help block this [64].
Additionally, CD40 signaling impacts resistance mecha-
nisms to chemotherapy. In CLL, CD40 activation triggersphosphorylation of ERK1/2 and IKK, and up-regulates
Mcl-1 and Bcl-xl, which creates a malignant phenotype
[64]. Similar mechanisms have been shown in Hodgkin
lymphoma (HL) [66]. The prognostic significance of CD40
expression on lymphoma cells [67] and/or the bone mar-
row stromal cells [68] as well as the impact of CD40-
related BCR signaling are areas of ongoing investigation.
Lucatumumab
Lucatumumab, a human anti-CD40 mAb, was shown to
cause more B-cell lysis than rituximab in preclinical
models [64]. In a phase 1 trial in CLL, stable disease (SD)
was observed in 17 of 26 patients [69]. In another
phase 1/2 trial of 111 patients with R/R NHL or HL, the
drug was well tolerated with ORR of 33% in FL patients
and 11% in those with DLBCL and marginal zone lymph-
oma (MZ) [70].
Dacetuzumab
Dacetuzumab is another CD40 mAb that acts as a partial
agonist at the CD40 receptor [71]. It works through direct
signal transduction, ADCC and ADP [71]. In lymphoma
xenograft models it demonstrates synergy with rituximab
and gemcitabine [72]. Dacetuzumab monotherapy appears
to be well tolerated and without major adverse events
(AEs) [73,74]. When combined with rituximab and gemci-
tabine for elderly patients with R/R DLBCL (n = 33) 47%
achieved a response (20% CR) [75]. These results are
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setting for DLBCL [76].
Targeting CD 52
The CD52 antigen is a cell surface glycoprotein of
unknown function that is expressed on both B- and
T-lymphocytes [77]. It is recognized by a humanized mAb
named alemtuzumab, which works by complement-
induced cell lysis, direct cell-mediated cytotoxicity and
induction of apoptosis [78-80].
Alemtuzumab
Alemtuzumab (Campath®) first received accelerated ap-
proval in the U.S. in 2001 for CLL patients who had
failed fludarabine. Then, based on the results of a trial
comparing alemtuzumab to chlorambucil as 1st-line
treatment, it received full approval in 2007 in the U.S.
and 2008 in Europe [81,82]. The subgroups that appeared
to benefit the most included patients with 17p deletion,
bone marrow infiltration and refractory autoimmune cy-
topenia [83]. In T-cell lymphomas (TCL), alemtuzumab
has shown efficacy as a single agent and in combination
with conventional chemotherapy in R/R or untreated
peripheral TCL (PTCL) as well as in advanced cutaneous
TCL (CTCL) [84-86].
More recent trials looked at improving the safety
profile of alemtuzumab, and its effectiveness in com-
bination with other regimens. Previous trials with alemtu-
zumab had been associated with significant toxicity,
stemming mainly from profound immunosuppression.
Lower doses of alemtuzumab showed similar effectiveness
with a better safety profile [87]. Subcutaneous alemtuzu-
mab in combination with rituximab in fludarabine-
refractory CLL patients was also well-tolerated and
allowed patients to achieve adequate cytoreduction
prior to stem cell transplantation [88]. A recent phase 2
trial tested alemtuzumab consolidation after CHO(E)
P-14 in 41 patients with untreated PTCL [89]. While
the combination was quite effective (59% of patients
achieved a CR), it was associated with significant
treatment-related adverse events (the main grade ¾
toxicities were infections and neutropenia, including
one potentially treatment-related death). Therefore, al-
though alemtuzumab is an active drug in lymphomas, its
use has been limited by its toxicities.
Targeting CCR4
The chemokine receptor CCR4 is expressed on a sub-
set of Type 2 helper (TH) and regulatory T-cells (Treg)
and is involved in lymphocyte trafficking. Many adult
PTCL express both CCR4 and its ligands. CCR4 (+)
T-cell lymphomas are associated with a poorer prog-
nosis, possibly because of downregulation of T-cell
mediated antitumor host response [90]. Mogamulizumab(KW–0761) is a mAb that targets CCR4(+) tumor cells by
ADCC and downregulates Treg trafficking to the tumor
microenvironment.
Mogamulizumab
Preliminary data shows responses in a subset of T-cell
lymphomas with traditionally poor prognosis. In a phase
1 trial of 16 patients with R/R CCR4(+) mature T-cell
lymphomas, 31% (n = 5) achieved a response (CR: 13%;
n = 2) [91]. Results of a phase 2 trial in 28 patients with
R/R CCR4(+) adult T-cell leukemia/lymphoma (ATLL)
showed an ORR of 50%, a median PFS of 5.2 months
and OS of 13.7 months, which lead to its approval in
Japan for this indication [92]. A US trial of single agent
mogamulizumab in patients with both CCR4(+) and
CCR4(−) R/R CTCL (n = 38) demonstrated an ORR of
35% [93]. In a consecutive study in patients with CCR4(+)
PTCL or CTCL (n = 38), the ORR was 35% (n = 13) and
14% (n =5) showed a CR with a median PFS of 3 months
[94]. Infusion reactions were common (59%), but only 2%
were grade III or higher. Skin and subcutaneous tissue dis-
orders occurred in 50% of patients with 12% being grade
III or higher. Viral reactivation, lymphopenia, and neutro-
penia were other notable AEs.
While CCR4 mAbs have primarily been studied in
T-cell NHL, it has been hypothesized that influencing
the tumor microenvironment by halting Treg traffick-
ing through CCR4 blockade may be broadly beneficial
in many cancers [95-98].
mAbs unblocking immune checkpoints
While most mAbs in this category only indirectly target
the lymphoma surface, they are included in this review
as they exemplify the concept of active immunotherapy.
PD-1/PD-L1 pathway
Programmed cell death 1 (PD-1) is a negative costimu-
latory receptor critical for the suppression of T-cell ac-
tivation. It is part of an immunoglobulin superfamily
(B7) and expressed on T- and B-lymphocytes, natural
killer (NK) cells, monocytes, and dendritic cells [99]. There
are two PD-1 ligands: PD-1 ligand 1 (PD-L1/B7-H1) and
PD-L2/B7-DC. The expression of PD-1 is significantly
increased on CD4+ and CD8+ Tcells following chronic ex-
posure and stimulation with antigens related to infection
or tumors [100].
On binding to its ligand, PD-1 generates a TCR–PD-1
microcluster [101], decreasing the phosphorylation of
the multiple downstream signaling molecules (including
Zap70, PI3K, and PKC-θ [102]) by recruiting SHP2, which
in turn results in the attenuation of T-cell activation and so
called “T-cell exhaustion”. Blockade of the PDL-1/PD-L2
and PD-1 interaction was shown to render previously aner-
gic T-cells responsive to antigen [103] (Figure 2).
Figure 3 The bispecific T-cell engager blinatumomab targeting
CD-19. Abbreviations: VL: variable region light chain; VH: variable
region heavy chain.
Figure 2 Mechanism of pidilizumab, which increases T cell
activation and cytokine release by inhibiting co-inhibitory
signaling up-regulated by tumors. Abbreviations: MHC Major
Histocompatibility Complex; TCR, T-cell Receptor; PDL-1, Programmed
Death Ligand 1; PD-1, Programmed Cell Death Protein 1.
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demonstrated in lymphomas [104]. PD-L1 expression
can be shown in a variety of B- and T-cell lymphomas
[105-108]. Additionally, expression of PD-1 peripheral
blood CD4+ and CD8+ lymphocytes has been described
as markedly elevated in patients with lymphomas, includ-
ing T-cell NHL, especially at the time of relapse [109].
Pidilizumab
Pidilizumab (formerly CT-011) is a humanized IgG-1κ
recombinant mAb that targets PD1. A phase 1 trial con-
ducted by Berger et al. [110] enrolled 17 patients with
advanced hematological malignancies including acute
myeloid leukemia (AML), CLL, NHL, HL and multiple
myeloma (MM). It concluded that CT-011 was safe and
well tolerated, with clinical benefit observed in 33%.
This was followed by a phase 2 international trial
studying patients with DLBCL, primary mediastinal B-cell
NHL or transformed indolent NHL, undergoing autolo-
gous stem cell transplant (ASCT) [111]. Patients received
pidilizumab for three cycles, beginning 30 to 90 days after
their ASCT. Among the 66 eligible patients, 16-month PFS
was 72% while 16-month OS was 85%. No severe unex-
pected toxicities, significant autoimmune toxicities or
treatment-related mortality was observed.
Another phase 2 study explored the efficacy of PD-1
blockade in combination with rituximab in relapsed
rituximab-sensitive FL (n = 30) [112]. Pidilizumab was
dosed every 4 weeks times four (additional doses for
patients with SD or better) with weekly rituximab infusions
times 4. Of 29 patients evaluable for activity, 19 (66%)
achieved an objective response. CR was identified in
15 (52%) and PR in 4 (14%) patients; median PFS was
18.8 months. The combination was well tolerated, with no
severe autoimmune or treatment-related AEs.Other mAbs targeting PD-1 or PD-L1 directly are
under investigation. While it appears that PD-L1 expres-
sion on tumor cells is a necessary prerequisit [113], fur-
ther research is needed to identify subsets of patients
who most likely benefit from blockade of this axis. Poten-
tial biomarkers of response are tumor infiltrating lympho-
cytes, certain T-effector cell gene signatures or increased
expression of PDL-1 in circulatory leucocytes [112].
Like PD-1, CTLA-4 is a negative regulator of T-cell
activation that serves to dampen antitumor immune re-
sponses. Its ligand, B7-1, is found on APCs, B-cells and
certain tumor cells. Blockade of CTLA-4 has yielded in-
creased T-cell mediated anti-tumor responses, most not-
ably in metastatic melanoma [114]. Ipilimumab (Yervoy®),
a CTLA-4 mAb, has been approved for treatment of meta-
static melanoma. In a phase 1 trial ipilimumab was used to
treat 18 patients with R/R DLBCL [115]. Responses were
seen in 2 patients (1 with a CR lasting >31 months) and
the drug was generally well tolerated, with diarrhea and
fatigue as the only severe AE. Larger studies are on-
going to further explore the use of CTLA-4 blockade
in hematological malignancies.
Unusual toxicities are a concern when unblocking im-
mune checkpoints. Even though preliminary studies in-
dicate that pidilizimab is well tolerated, studies involving
other PD-1 inhibitors (e.g. nivolumab) and CTLA-4 mAbs
have reported a myriad of AEs, including 3 treatment-
related deaths reported with the use of nivolumab due
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disorders such as endocrinopathies (e.g. hypophysitis,
hypothyroidism), skin disorders (e.g. rash, vitiligo), pneu-
monitis and colitis [116].
Bispecific T-cell engagers (BiTE)
BiTE molecules are engineered to contain the variable
domains of two antibodies joined together: one antibody
binds CD19 and one binds the CD3 antigen of T-cells.
When bound to a CD3/CD19 complex, a BiTE brings
the two cells in close proximity and thus activates T-cells
to destroy the tumor cell via perforin-mediated apoptosis
(Figure 3) [117].
Blinatumomab
Blinatumomab is a BiTE molecule that has been the
forerunner of BiTE molecule testing and stands for
B-lineage anti-tumoral mAb. Promising activity has been
demonstrated in patients with B-lineage ALL, specifically
in MRD eradication [118-120].
The first phase 1 trial of blinatumomab as single agent
given as continuous intravenous infusion in NHL began
in 2004. The initial cohort of 38 patients had R/R B-cell
NHL and received a continuous infusion at different
doses for 4–8 weeks. Eleven patients (28.9%) had meas-
urable response after treatment; 4 (11%) achieved a CR
and 7 (18%) a PR [121]. The trial established the maximum
tolerated dose (MTD) of 60 μg/m2/d. By 2011, the study
had enrolled 62 patients. Of the 22 patients who received
the MTD, 18 (82%) showed an objective response and dur-
ation of response lasted up to 32 months.
Because of its clinical benefits and tolerability in indo-
lent lymphomas, the study was expanded to include pa-
tients with DLBCL [122]. Twelve patients were enrolled
with 9 patients evaluable for response. Five out of 9 pa-
tients (56%) showed responses, the longest lasting
428 days. This set the stage for a phase 2 trial of blinatu-
momab in R/R DLBCL. Of the 11 patients recruited so
far, 7 were evaluable for response: 3 patients experienced
progression of disease, while 4 responded resulting in an
ORR of 57% [120].
The most common clinical AEs regardless of grade in-
cluded pyrexia, fatigue, headache, diarrhea, and weight
increase. The dose-limiting factor was CNS related toxicity
ranging from tremor, disorientation, speech disorder, cere-
bellar symptoms, to seizures.
While the results are intriguing, the optimal setting
for blinatumomab in lymphomas remains to be defined.
Multiple trials studying blinatumomab in B-cell malig-
nancies are ongoing, the focus being B-lineage ALL.
Conclusion
Tremendous advances have been made in targeting the
lymphoma surface. Initially only seen as a way to moreprecisely target tumors, actively harnessing the ability of
the patients’ own immune system in the fight against
cancer is revolutionizing therapy. This involves rethink-
ing current treatment paradigms in terms of response
assessment [123] and side effect management. Unleash-
ing the immune system can result in never-before en-
countered side effects. While results are promising, one
remaining challenge is to identify which patient will re-
spond to immunotherapy. Nevertheless, next to the clas-
sical modalities surgery, radiation, chemotherapy, and
more recently molecularly targeted therapies, many regard
immunotherapy now as the fifth pillar of oncology [124].
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